NasdaqGS:TRIB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe.


Snowflake Analysis

Moderate growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has Trinity Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TRIB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.5%

TRIB

0.9%

US Medical Equipment

1.3%

US Market


1 Year Return

15.8%

TRIB

18.2%

US Medical Equipment

14.9%

US Market

Return vs Industry: TRIB matched the US Medical Equipment industry which returned 15.6% over the past year.

Return vs Market: TRIB exceeded the US Market which returned 12.5% over the past year.


Shareholder returns

TRIBIndustryMarket
7 Day-8.5%0.9%1.3%
30 Day8.7%8.8%4.7%
90 Day40.7%13.8%17.1%
1 Year15.8%15.8%19.2%18.2%17.3%14.9%
3 Year-55.9%-55.9%73.6%68.9%38.9%29.9%
5 Year-85.6%-85.6%119.9%102.7%71.3%52.8%

Price Volatility Vs. Market

How volatile is Trinity Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Trinity Biotech undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TRIB ($2.49) is trading below our estimate of fair value ($7.59)

Significantly Below Fair Value: TRIB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TRIB is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: TRIB is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TRIB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TRIB is overvalued based on its PB Ratio (67.8x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is Trinity Biotech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

151.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TRIB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: TRIB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TRIB's is expected to become profitable in the next 3 years.

Revenue vs Market: TRIB's revenue (1.3% per year) is forecast to grow slower than the US market (9.3% per year).

High Growth Revenue: TRIB's revenue (1.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TRIB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Trinity Biotech performed over the past 5 years?

-42.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TRIB is currently unprofitable.

Growing Profit Margin: TRIB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TRIB is unprofitable, and losses have increased over the past 5 years at a rate of 42.5% per year.

Accelerating Growth: Unable to compare TRIB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRIB is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.5%).


Return on Equity

High ROE: TRIB has a negative Return on Equity (-4026.69%), as it is currently unprofitable.


Next Steps

Financial Health

How is Trinity Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: TRIB's short term assets ($67.5M) exceed its short term liabilities ($22.1M).

Long Term Liabilities: TRIB's short term assets ($67.5M) do not cover its long term liabilities ($106.3M).


Debt to Equity History and Analysis

Debt Level: TRIB's debt to equity ratio (8077.6%) is considered high.

Reducing Debt: TRIB's debt to equity ratio has increased from 1.2% to 8077.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TRIB has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TRIB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Trinity Biotech current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TRIB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TRIB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TRIB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TRIB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: TRIB is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TRIB's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.8yrs

Average board tenure


CEO

Ronan O’Caoimh (64yo)

11.83yrs

Tenure

US$425,000

Compensation

Mr. Ronan O'Caoimh co-founded Trinity Biotech PLC in June 1992 and has been its Chief Executive Officer since October 2008. Mr. O'Caoimh served as Chief Executive Officer of Trinity Biotech PLC from March  ...


CEO Compensation Analysis

Compensation vs Market: Ronan's total compensation ($USD425.00K) is below average for companies of similar size in the US market ($USD608.75K).

Compensation vs Earnings: Ronan's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Ronan O’Caoimh
Chairman & CEO11.83yrsUS$425.00k8.44% $4.4m
Kevin Tansley
Chief Financial & Accounting Officer3.92yrsUS$630.00k0.18% $93.4k
James Walsh
Executive Director13.58yrsno data1.92% $997.4k
Clinton Severson
Independent Non-Executive Director11.75yrsUS$75.00k0.37% $191.7k
Denis Burger
Lead Independent Directorno dataUS$75.00kno data
James Merselis
Independent Non-Executive Director11.5yrsUS$75.00kno data

11.8yrs

Average Tenure

65yo

Average Age

Experienced Board: TRIB's board of directors are seasoned and experienced ( 11.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Trinity Biotech plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Trinity Biotech plc
  • Ticker: TRIB
  • Exchange: NasdaqGS
  • Founded: 1992
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$52.045m
  • Shares outstanding: 20.90m
  • Website: https://www.trinitybiotech.com

Number of Employees


Location

  • Trinity Biotech plc
  • IDA Business Park
  • Bray
  • Co. Wicklow
  • Ireland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRIBNasdaqGS (Nasdaq Global Select)YesADR EACH REPR 4 CLS'A'ORD USD0.019USUSDOct 1992
TRBADB (Deutsche Boerse AG)YesADR EACH REPR 4 CLS'A'ORD USD0.019DEEUROct 1992

Biography

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the United States, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and distributes products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. The company sells its products through its direct sales force; and a network of independent distributors and strategic partners. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/02 23:33
End of Day Share Price2020/07/31 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.